Trials / Unknown
UnknownNCT03099330
A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics
Phase I Study of Tolerance and Pharmacokinetics of TQ-B3139 in Patients With Advanced Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study of TQ-B3139, inhibitor of ALK/C-Met tyrosine kinase, in patient with advanced cancer
Detailed description
phase I of safety, pharmacokinetic and pharmacodynamic study of TQ-B3139. To recommend a reasonable dose and indication for subsequent research.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3139 | TQ-B3139 p.o. qd |
Timeline
- Start date
- 2017-07-19
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2017-04-04
- Last updated
- 2017-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03099330. Inclusion in this directory is not an endorsement.